The Conversation (0)
The Chiesei Group, an Italian conglomerate, said Monday it has agreed to acquire Zymenex Holding A/S and its related group of companies (“Zymenex”), a biopharmaceutical group focused on research and development of biologic therapeutics for the treatment of rare and life threatening genetic diseases.
The Chiesei Group, an Italian conglomerate, said Monday it has agreed to acquire Zymenex Holding A/S and its related group of companies (“Zymenex”), a biopharmaceutical group focused on research and development of biologic therapeutics for the treatment of rare and life threatening genetic diseases. Terms of the transaction were not disclosed.
As quoted in the news release:
“We are excited to announce this transaction, which marks Chiesi’s entrance into the rare disease space and provides an opportunity to access high-potential markets,” said Ugo Di Francesco, CEO of Chiesi. “By expanding our research and development assets and know-how, we believe we can successfully commercialize new and developing drugs to enhance our portfolio, expand our international footprint and strengthen our competitive position.”
Read the full press release by Zymenex Holding A/S and Chiesi Farmaceutical S.p.A.